Actuate Therapeutics Inc
ACTU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,178 | $2,765 | $3,220 | $3,686 |
| G&A Expenses | $3,294 | $3,204 | $3,145 | $2,873 |
| SG&A Expenses | $3,294 | $3,204 | $3,145 | $2,873 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,472 | $5,969 | $6,366 | $6,559 |
| Operating Income | -$5,472 | -$5,969 | -$6,366 | -$6,559 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $65 | $19 | $49 | $113 |
| Pre-Tax Income | -$5,407 | -$5,949 | -$6,317 | -$6,446 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,407 | -$5,949 | -$6,317 | -$6,446 |
| % Margin | – | – | – | – |
| EPS | -0.25 | -0.3 | -0.32 | -0.6 |
| % Growth | 16.7% | 6.3% | 46.7% | – |
| EPS Diluted | -0.25 | -0.3 | -0.32 | -0.6 |
| Weighted Avg Shares Out | 21,395 | 19,646 | 19,498 | 19,515 |
| Weighted Avg Shares Out Dil | 21,395 | 19,646 | 19,498 | 19,515 |
| Supplemental Information | – | – | – | – |
| Interest Income | $70 | $25 | $54 | $118 |
| Interest Expense | $5 | $5 | $5 | $5 |
| Depreciation & Amortization | $0 | $0 | $0 | $118 |
| EBITDA | -$5,402 | -$5,944 | -$6,312 | -$6,323 |
| % Margin | – | – | – | – |